Immuvera Therapeutics today announced the appointment of Amir Sheikh as Fractional CFO, strengthening the company’s leadership team as it prepares for its upcoming financing activities and continued development of Nebumet, the company’s inhaled immunotherapy program in veterinary oncology.

Amir brings more than 15 years of experience across medtech, pharma and life sciences companies, with a track record spanning venture-backed start-ups, scale-ups and regulated operating environments. His background includes fundraising support from early-stage through growth rounds, financial modelling and forecasting, board and investor reporting, operational finance, and the build-out of finance functions in highly regulated businesses.

In his role with Immuvera, Amir will support the company’s capital raise preparations, financial planning, investor materials, due diligence readiness and broader financial strategy as the business advances toward its next phase of growth.

“We are pleased to welcome Amir to Immuvera at an important stage for the company,” said Jørund Sollid, CEO of Immuvera Therapeutics. “His combination of strategic finance, fundraising experience and operational understanding of life sciences businesses will be valuable as we continue building the company.”

“I’m excited to join Immuvera as CFO and support the team during this important period,” said Amir Sheikh. “The company is addressing a significant unmet need in veterinary oncology, and I look forward to helping position the business for a successful financing process and long-term value creation.”

Immuvera Therapeutics is a Norwegian veterinary oncology company developing inhaled immunotherapies . Its lead product candidate, Nebumet, is being developed to help prevent and treat lung metastases.

About Immuvera Therapeutics
Immuvera Therapeutics is a Norwegian veterinary oncology company focused on inhaled immunotherapies for metastatic cancer in dogs. The company’s lead program, Nebumet, is an off-the-shelf inhaled immunotherapy being developed to address lung metastases in canine cancer.